| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.059 | 0.2 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | -0.057 | 0.2 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.056 | 0.3 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | 0.049 | 0.3 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | 0.044 | 0.3 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.04 | 0.4 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.039 | 0.4 |
| mRNA | PD-0332991 | CCLE | pan-cancer | AAC | 0.036 | 0.5 |
| mRNA | AEW541 | CCLE | pan-cancer | AAC | -0.024 | 0.6 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | 0.018 | 0.7 |